Theradiag's share price edged up 0.7% on the Paris Bourse on Monday, as investors were reassured by the unsurprising sales figures published by the diagnostics specialist this morning.

The Group reported annual sales of 12.2 million euros for the 2022 financial year, up 9.7%, driven in particular by a strong performance in exports (excluding the USA), with growth of +23.3%.

In theranostics (the combination of treatment and diagnostics, which measures the efficacy of biotherapies in the treatment of chronic diseases, and enables them to be properly implemented), growth reached 10.1%

The historical in vitro diagnostics business posted sales growth of 9.2% to 5.8 million euros.

At December 31, 2022, Theradiag's cash position stood at 6.4 million euros, compared with 7.1 million euros at December 31, 2021, a level deemed 'in line with the company's business plan'.

Following its tender offer, which closed last week, Biosynex held more than 68.8% of Theradiag's capital and at least 68.6% of its voting rights, meaning that the minimum condition of the offer has been met.

Copyright (c) 2023 CercleFinance.com. All rights reserved.